Eurobio Scientific: 2025 FY revenue

Core Insights - Eurobio Scientific reported a revenue of €168 million for the fiscal year ending December 31, 2025, marking a 9% increase from €154.2 million in 2024, with a pro forma growth of 2.3% when excluding acquisition impacts [3][4] Financial Performance - Revenue growth was primarily driven by an increase in France, contributing €5.2 million, influenced by non-recurring factors such as Chikungunya and Dengue epidemics and the extension of certain tenders in Transplantation [3] - The GenDx subsidiary generated €33.5 million in revenue, reflecting a 9% increase in 2025 [3] - Proprietary products accounted for 35% of total revenue, with a growth of over 20% compared to 2024 [6] - International sales represented 42% of total revenue, attributed to acquisitions and significant growth in the U.S. and Canada [7] Strategic Developments - The Group is focused on geographic and technological expansion, aiming to become a major player in specialty diagnostics [5] - Recent acquisitions include Quimark and the Life Sciences unit of Voden Medical Instruments Spa, contributing €1.2 million and €4.1 million to revenue, respectively [10] - A distribution agreement with Seegene generated approximately €48 million in revenue for fiscal year 2025, with discussions ongoing regarding the transition as the agreement nears expiration [11][12] Future Outlook - Eurobio Scientific is committed to accelerating its strategic priorities, including the development of proprietary products and international market expansion [13]